FDA approves the first pill in a cholesterol drug class that has only ever been injectable

The FDA has approved Lipfendra (enlicitide), the first oral inhibitor of PCSK9 — a cholesterol-lowering drug class that, until now, existed only as an injection. The agency's own novel drug approvals log lists the approval date as 15 July, with the public announcement following on 17 July [s1, s2]. Lipfendra is approved as an adjunct to diet and exercise for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia, who need further LDL-C reduction beyond their existing therapy [s1].

What the drug does, and what changes about how it's taken

PCSK9 — proprotein convertase subtilisin/kexin type 9 — is a protein that interferes with the liver's ability to clear LDL cholesterol from the blood. Drugs that inhibit it, first approved roughly a decade ago, have become a standard add-on option for patients whose LDL-C remains too high on statins alone. Every prior PCSK9 inhibitor available in the US has required injection, typically every two to four weeks [s1]. Lipfendra is a once-daily tablet [s1].

That format change matters clinically because injectable PCSK9 inhibitors, despite their effectiveness, have had persistently low uptake — a pattern widely attributed in part to needle aversion, injection logistics, and the friction of a delivery method that differs from the pill-based regimens patients are already managing for other conditions. An oral option does not change the underlying biology, but it removes one of the most commonly cited practical barriers to starting or staying on the drug class.

What the trial evidence shows

FDA's approval rests on two randomized, double-blind, placebo-controlled trials enrolling a combined 3,207 adults with hypercholesterolemia, all already on maximally tolerated statin therapy [s1]. Both trials measured percent change in LDL-C from baseline to week 24 as their primary endpoint.

The first trial enrolled adults with established atherosclerotic cardiovascular disease or at high risk for it; participants had a mean baseline LDL-C of 96 mg/dL, and Lipfendra produced an average 56 percent reduction versus placebo at 24 weeks [s1]. The second trial enrolled adults with heterozygous familial hypercholesterolemia, a genetic condition that causes lifelong elevated LDL-C; participants had a mean baseline LDL-C of 119 mg/dL, and Lipfendra produced a 59 percent reduction versus placebo [s1]. Both reductions are placebo-adjusted figures, meaning they represent the drug's effect above and beyond whatever LDL-lowering statin therapy alone was already achieving.

Safety findings were reassuring but not entirely clean. In the first trial, adverse reaction rates were similar between Lipfendra and placebo groups. In the second, the most common adverse reactions occurring more often with Lipfendra than placebo were diarrhea and dizziness [s1]. Discontinuation rates due to adverse reactions were comparable between groups across both trials [s1].

Why the approval pathway is itself part of the story

Lipfendra received Priority Review, and its application was also reviewed under the FDA's Commissioner's National Priority Voucher pilot program, which is designed to accelerate review for therapies addressing national public health priorities [s1]. Cardiovascular disease is the leading cause of death in the United States, and the FDA's acting Center for Drug Evaluation and Research director, Michael Davis, framed the approval in that context: "Cardiovascular disease remains the leading cause of death in the United States, and elevated LDL cholesterol is one of its most important modifiable risk factors. This approval provides an additional treatment option for adults with hypercholesterolemia and reflects the FDA's broader commitment to supporting meaningful advances in patient access and tackling chronic diseases" [s1]. The approval was granted to Merck Sharp & Dohme LLC [s1].

What an oral option changes, and what it doesn't

Nothing in the approval alters where PCSK9 inhibitors sit in the broader treatment sequence: statins remain first-line therapy for most patients with high LDL-C, and PCSK9 inhibitors — oral or injectable — are additive options for people who need further reduction or cannot tolerate statins adequately. A 56-to-59 percent placebo-adjusted LDL reduction is substantial and in line with what injectable PCSK9 inhibitors have shown in their own trials, but the two formats have not been compared head-to-head in the trials supporting this approval, so claims about relative effectiveness between oral and injectable versions would outrun the available evidence.

What to watch

Real-world uptake will be the test of whether the format change actually expands access to PCSK9 inhibition, or whether cost and insurance coverage — historically significant barriers for this drug class regardless of delivery method — remain the binding constraint. Pricing and payer coverage decisions, not yet public at the time of approval, will likely determine how much of the theoretical adherence advantage of a pill translates into practice. This article describes clinical trial results and regulatory action; it is not a recommendation regarding any individual's treatment, which should be discussed with a healthcare provider.

Sources

• [s1] U.S. Food and Drug Administration, "FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol," press announcement, 17 July 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol
• [s2] U.S. Food and Drug Administration, "Novel Drug Approvals for 2026," accessed 24 July 2026 (listing Lipfendra approval date as 15 July 2026). https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026